Study Details

Open

First in Human Study of IMGN151 in adut patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers.

The purpose of this study is to test the safety and effectiveness of the test drug IMGN151-1001 on your cancer.

Age & Gender

18 years ~ 99 years
Female

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

This study aims to treat your cancer and closely resembles routine care that would be received regardless of participating on a research study. To participate on the study, you will frequently meet with a member of the study team in addition to your oncology care team. The study involves Blood and urine tests, an ophthalmic eye exam, a tumor sample, CT or MRI scans, physical exams, study drug.

Incentives

travel stipend/ $75 per visit, travel Mileage, hotel reimbursement

In-person visits:
up tp 20

Total length of participation:
Up to 2 years

Looking for Specific Volunteers

Able to participate:

you have a confirmed diagnosis of recurrent endometrial cancer or high-grade serous epithelial ovarian cancer (EOC), primary peritoneal, or fallopian tube cancer. (Dose-escalation phase
you have a confirmed diagnosis of recurrent endometrial cancer or platinum-resistant, high-grade serous epithelial ovarian cancer (PROC), primary peritoneal, or fallopian tube cancer. (Dose Epansion
have prior anticancer therapy
you have evaluable lesions
you have completed any major surgery at least 4 weeks before the first dose of IMGN151 and have recovered or stabilized from the side effects

Not eligible if:

have ovarian cancer with histologies including endometriod, clear cell, mucinous or sarcomatous histology
you had Radiation Therapy of >20% of the potentila bone marrow
you have > Grade 1 peripheral neuropathy
you are pregnant or breasfeeding
you have active or chronic corneal disorders

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Linda Van Le
Obstetrics and Gynecology - Gynecologic Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Uterine (endometrial), Ovarian)

IRB Number

23-3065

ClinicalTrials.gov

NCT05527184